AstraZeneca Pharma surges on getting nod to import for sale, distribution of Trastuzumab deruxtecan lyophilized powder
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Astrazeneca Pharma India is currently trading at Rs. 5258.00, up by 198.45 points or 3.92% from its previous closing of Rs. 5059.55 on the BSE.
The scrip opened at Rs. 5100.00 and has touched a high and low of Rs. 5300.00 and Rs. 5100.00 respectively. So far 465 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 7208.00 on 06-Feb-2024 and a 52 week low of Rs. 3102.00 on 20-Apr-2023.
Last one week high and low of the scrip stood at Rs. 5300.00 and Rs. 4050.15 respectively. The current market cap of the company is Rs. 13142.13 crore.
The promoters holding in the company stood at 75.00% while Institutions and Non-Institutions held 5.42% and 19.58% respectively.
AstraZeneca Pharma India has received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India.
Trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-Low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
It is also indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab based regimen.
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) in India for the specified additional indications, subject to the receipt of related statutory approvals, if any.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
